Skip to main content
LQDA
NASDAQ Life Sciences

Director-Affiliated Entity Files to Sell $12.8M in Liquidia Stock

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$63.9
Mkt Cap
$5.683B
52W Low
$11.85
52W High
$66.775
52W Position info
439% above low
Off High info
4.3% below high
Rel. Volume info
2.1× avg
Market data snapshot near publication time

LQDA has more than doubled off its 52-week low of $11.85 on elevated volume (2.1× avg).

Summary

A director-affiliated entity, Canaan VIII LP, plans to sell $12.8 million in Liquidia Corp stock, extending a recent trend of significant insider distribution while the stock is near its 52-week high.


Key Events · Ownership and Investor Activity · LQDA

  • Intent to Sell $12.8 Million in Stock

    Canaan VIII LP, an entity affiliated with a director, filed a Form 144 to sell 200,000 shares of common stock, valued at approximately $12.8 million.

  • Continuation of Insider Distribution

    This filing follows multiple previous Form 144s from Canaan VIII LP and other insiders, contributing to a net insider selling of over $66 million in the last 90 days.

  • Selling Near 52-Week Highs

    The proposed sale occurs as Liquidia's stock is trading near its 52-week high of $66.775, potentially indicating profit-taking by the affiliated entity.


Analysis · LQDA · Life Sciences

Canaan VIII LP, an entity affiliated with a director, has filed a Form 144 indicating its intent to sell an additional $12.8 million worth of Liquidia common stock. This filing continues a pattern of significant insider selling from this entity and other insiders, occurring while the stock trades near its 52-week high. The ongoing distribution by a director-affiliated entity could signal a lack of conviction at current valuations.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LQDA was trading at $63.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.7B. The 52-week trading range was $11.85 to $66.78. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LQDA - Latest Insights

LQDA
Nov 10, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $47.45
Real-time Price: $54.75 info
Change: +$7.30 (+15%) info
Market Cap: $4.904B info
LQDA
Nov 10, 2026, 6:45 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $47.40
Real-time Price: $54.75 info
Change: +$7.35 (+16%) info
Market Cap: $4.904B info
LQDA
Nov 10, 2026, 6:30 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $50.00
Real-time Price: $54.75 info
Change: +$4.75 (+10%) info
Market Cap: $4.904B info
LQDA
Oct 13, 2026, 9:49 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $39.50
Real-time Price: $54.75 info
Change: +$15.25 (+39%) info
Market Cap: $4.904B info
LQDA
Oct 13, 2026, 5:50 PM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $31.76
Real-time Price: $54.75 info
Change: +$22.99 (+72%) info
Market Cap: $4.904B info